Cyclic Versus Daily Teriparatide on Bone Mass

PHASE2UnknownINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

February 29, 2016

Study Completion Date

November 30, 2017

Conditions
Osteoporosis
Interventions
DRUG

Teriparatide

Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.

DRUG

Alendronate

Participants will take 70 mg per week of alendronate for 48 months.

DIETARY_SUPPLEMENT

Calcium

Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.

DIETARY_SUPPLEMENT

Vitamin D3

Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.

Trial Locations (1)

10993

Helen Hayes Hospital, West Haverstraw

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

collaborator

Health Research, Inc.

OTHER

lead

Helen Hayes Hospital

OTHER

NCT00668941 - Cyclic Versus Daily Teriparatide on Bone Mass | Biotech Hunter | Biotech Hunter